Tennessee Governor Bill Lee, along with Economic and Community Development Commissioner Stuart C. McWhorter and Harrow, Inc. CEO Mark L. Baum, announced today that Harrow is expanding its corporate headquarters…
Fujirebio has announced that its subsidiary, Fujirebio Diagnostics, Inc., has submitted the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test to the U.S. Food and Drug Administration…
Omnicell, Inc. (Nasdaq: OMCL), a leader in transforming pharmacy care delivery, has announced the appointment of Nnamdi Njoku as Executive Vice President and Chief Operating Officer, effective October 7, 2024.…
Medidata, a Dassault Systèmes brand and a leader in clinical trial solutions for the life sciences industry, has introduced Medidata Patient Payments, a new solution designed to simplify the process…
Takeda (TSE:4502/NYSE) has announced that the Japanese Ministry of Health, Labour and Welfare has approved the manufacture and marketing of FRUZAQLA Capsules (1mg/5mg), containing fruquintinib, a selective oral inhibitor targeting…
Zenyaku Kogyo Co., Ltd. (Japanese-only website) and Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) have announced that Zenyaku has received regulatory approval from the Ministry of Health, Labour and Welfare (MHLW)…
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced the launch of its new cobas® Respiratory flex test, the first to incorporate Roche’s proprietary TAGS (Temperature-Activated Generation of Signal) technology. This…
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), proudly announces the next chapter of its 2024 BOTOX® Cosmetic grant program, focused on empowering women entrepreneurs. This phase introduces crowdfunding campaigns…
The Ministry of Health, Labour and Welfare of Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL injection for IV infusion every four weeks), Eli Lilly and Company’s (NYSE: LLY) treatment…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced that it has filed for regulatory approval to launch a Phase 1/2a clinical trial for ARO-INHBE, its investigational RNA interference (RNAi) therapeutic aimed…
a leading precision medicine company utilizing artificial intelligence (AI) to enhance cancer treatment, has announced its expansion into human oncology. Building on its successful work in veterinary oncology, ImpriMed will…
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven biotech company focused on developing targeted cancer therapies through its proprietary RADR® AI and machine learning platform, announced that the FDA has granted…